In conclusions, several studies demonstrated that SSc is a Th17-dominant disease in Treg/ Th17 balance and the inhibition of the indirect effects of IL-17 on T and B cell subsets correlated by brodalumab may ameliorate fibrotic skin lesions [184,185,186,187,188,189,190,191,193,194]. Here, IL17A is linked to systemic sclerosis.